Menu
Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
@ExonateUK on Twitter
Exonate is extremely proud to support WDD (World Diabetes day.) The campaign draws attention to issues of paramount importance to the diabetes world and keeps diabetes firmly in the public and political spotlight.
#NursesMakeTheDifference #WorldDiabetesDay
Really excited that Exonate’s CEO Catherine Beech, is attending, the Glocal Innovation Life Sciences meet-up November 11th. Bringing together the thought-leadership community from the UK, Europe, Australia, and New Zealand forming a global network of life sciences professionals.
Catherine Beech, CEO Exonate is very excited to feature in the Alumni section of the seventh annual of Movers and Shakers in BioBusiness reporting highlights of 30 examples of resourceful leaders in the UK bioscience sector, released today by BioBeat.
#biobeat20 #exonate
Delighted that Dr Catherine Beech, will be attending the Drug Delivery Innovation Showcase on November 5th, hosted by the Ophthalmology Innovation Summit. This showcase will focus on exciting innovative methods for ocular drug delivery!
#aao2020 #exonate #lifesciences
Really excited that our CEO,
@Beech_Catherine
representing us at #biotrinity conference 28th April-1st May, joining a fantastic line-up of speakers and is featured in a 30-minute case study showcasing her career path, business strategy and the importance of a strong team
Wonderful news Exonate have been shortlisted into the final round in the Most Impactful UK Deal category of the 2020 OBN Awards on the 26th November 2020
Patients with diabetic macular oedema receiving anti-VEGF injections have worse outcomes than in clinical trials, likely due to undertreatment. Reducing the need for injections with new treatments could help improve patient outcomes @ExonateUK https://twitter.com/ClinExpOphthal/status/1296760702170853376
10 yr outcomes of anti‐VEGF for neovascular #maculardegeneration. 10% gained, 64% lost ≥10 letters, 23% remained stable; 93% geographic atrophy, 71% subretinal fibrosis. Vision worse in pre‐treated eyes than naïve. Wolff et al.
https://doi.org/10.1111/ceo.13742
